US3863011A - Process for treating neuroendocrinopathic diseases employing pimozide - Google Patents
Process for treating neuroendocrinopathic diseases employing pimozide Download PDFInfo
- Publication number
- US3863011A US3863011A US374454A US37445473A US3863011A US 3863011 A US3863011 A US 3863011A US 374454 A US374454 A US 374454A US 37445473 A US37445473 A US 37445473A US 3863011 A US3863011 A US 3863011A
- Authority
- US
- United States
- Prior art keywords
- pimozide
- compound
- patient
- bis
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 15
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims description 19
- 230000008569 process Effects 0.000 title claims description 14
- 229960003634 pimozide Drugs 0.000 title abstract description 12
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 14
- 230000002267 hypothalamic effect Effects 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 12
- 210000002381 plasma Anatomy 0.000 claims description 12
- 102000005726 Pituitary Hormone-Releasing Hormones Human genes 0.000 claims description 6
- 108010031037 Pituitary Hormone-Releasing Hormones Proteins 0.000 claims description 6
- 239000000474 Pituitary Hormone-Releasing Hormone Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 2
- QOYHHIBFXOOADH-UHFFFAOYSA-N 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 QOYHHIBFXOOADH-UHFFFAOYSA-N 0.000 abstract description 8
- 229960003532 fluspirilene Drugs 0.000 abstract description 7
- 241000700159 Rattus Species 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 10
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 6
- 102000009151 Luteinizing Hormone Human genes 0.000 description 6
- 108010073521 Luteinizing Hormone Proteins 0.000 description 6
- 229940040129 luteinizing hormone Drugs 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 102100021752 Corticoliberin Human genes 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- MKJDUHZPLQYUCB-UHFFFAOYSA-N decan-4-one Chemical compound CCCCCCC(=O)CCC MKJDUHZPLQYUCB-UHFFFAOYSA-N 0.000 description 4
- 208000030172 endocrine system disease Diseases 0.000 description 4
- 108090000340 Transaminases Proteins 0.000 description 3
- 102000003929 Transaminases Human genes 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003836 peripheral circulation Effects 0.000 description 2
- 239000003488 releasing hormone Substances 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- XXAXVMUWHZHZMJ-UHFFFAOYSA-N Chymopapain Chemical compound OC1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1O XXAXVMUWHZHZMJ-UHFFFAOYSA-N 0.000 description 1
- 108090001069 Chymopapain Proteins 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 201000010272 acanthosis nigricans Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229950002007 estradiol benzoate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 239000002303 hypothalamus releasing factor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 208000001061 polyostotic fibrous dysplasia Diseases 0.000 description 1
- 208000006155 precocious puberty Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
Definitions
- the clinical manifestations of lipodystrophic diabetes are alleviated by administration of either l- ⁇ -[4,4-bis-(p-fluorophenyl) butyll-4-piperidyl ⁇ -2-benzimidaz0lin0ne or 8-[4,4- bis(p-flu0rophenyl)butyl I- I -pheny
- Exemplary of endocrinopathy is lipodystrophic diabetes, a rare and bizarre genetically transferred disease characterized by loss of subcutaneous and other body fat, skeletal and muscle over growth, splenomegaly and hepatomegaly due to fat infiltration, genital enlargement, hyperpigmentation with acanthosis nigricans, insulin-resistant hyperglycemia, hyperlipemia and hyperinsulinemia.
- releasing factors corticotropin releasing factor CRF, follicle stimulating hormone releasing factor FRF, melanocyte stimulating hormone releasing factor MRF and luteinizing hormone releasing factor LRF
- CRF, FRF and LRF are present inperipheral plasma of ahypophysectomized human and that CRF, FRF and LRF are detectable in the peripheral plasma of hypophysectomized rats. l-leretofore, there has been no known effective treatment of patients suffering from lipodystrophic diabetes.
- the compound ⁇ -1- 4,4-bis(p-fluorophenyl)butyl]4-piperidyl ⁇ 2- benzimidazolinone is a known neuroleptic agent (J. Clinical Pharm., vol. 12 (1) pp. 26-34 (1972), commonly referred to as Pimozide, and presents the structure Likewise, the analogue 8-[4,4-bis(pfluorophenyl)butyl]-l-phenyl-l,3,6-triazaspiro (4.5)decan-4-one, is a known compound commonly referred to as Fluspiriline, which presents the structure DESCRIPTION OF THE INVENTION In accordance with this invention.
- a method for alleviating the clinical manifestations of endocrinopathies induced by hypothalamic hyperfunction comprises administering an effective amount of either 1-- ⁇ -l-[4,4-bis(p-fluorophenyl)butyll-4-piperidyll-Z- benzimidazolinone or 8-l4.4-bis(p-fluorophenyl )butyll-phenyll ,3,8triazaspiro(4.5)decan-4-one to an afflicted patient.
- a method for alleviating the clinical manifestations oflipodystrophic diabetes which comprises administering an effective amount of either 1-- ⁇ -l-[4,4-bis(p-fluorophenyl)butyl]-4-piperidyl ⁇ -2- benzimidazolinone or 8-[4,4-bis(pfluorophenyl)butyl l -phenyl-l ,3,8-triazaspiro( 4.5 decan-4-one to an afflicted patient.
- a dosage of 8.0 milligrams per day, administered orally, chronically has been found to be effective in the treatment of lipodystrophic diabetes.
- control of the disease is obtained by oral administration of 8.0 milligrams at intervals within the range of from 16 to 48 hours, chronically.
- the size of an individual dose as well as the regimen may be varied to achieve the desired results by the attending physician.
- the dosage range for treatment of endocrinopathic diseases induced by hypothalamic hyperfunction is the same as that employed for the treatment of schizophrenia, or from about 4 to about 16 milligrams per day.
- Both Pimozide and Fluspiriline may be administered orally or parenterally as neat or pure compounds without additives other than for purposes of providing suitable pharmaceutical solution or liquid suspension.
- conventional adjuvants known to the art may be combined with the active compounds of this invention to provide compositions and solutions if desired for producing tablets, capsules, injectables, and the like, without adverse effect upon the properties of the compounds.
- a compound active in reducing the concentration of LH releasing-factor in peripheral circulation can be identified by observing the decrease of plasma LH increments in steroid-blocked ovariectomized rats treated with the plasma from the hypophysectomized rats.
- the change in luteinizing hormone in the recipient rats blood was determined in absolute level values by withdrawing an initial blood sample (1.0 ml.) from the anesthetized (ether) rat followed by a second blood sample (1.0 ml.) 20 minutes after administration of the peripheral plasma from the hypophysectomized female, Sprague-Dawley rat.
- the difference in luteinizing hormone content of the blood was determined from the preand post-treated assay rats and the data are expressed in terms of percentage change.
- the serum was assayed for luteinizing hormone according to the double antibody radioimmuno-assay procedure of G. N. Niswender et. al., Proc. Soc. Exp. Bio. Med., vol. 128, page 807 (1968).
- FIG. 1 presents the results of the above described testing on a statistically significant number of standard experimental animals, the data for which is too voluminous to present in detail.
- the vertical axis representing the percent change in luteinizing hormone found in the serum of the experimental animals.
- the first two bars of the graph represent the change observed upon administration of serum from normal (non-hypophysectomized) rats to the blocked, ovariectomized rats.
- the change in luteinizing hormone content of the recipient rats was quite small, demonstrating the absenceof any appreciable amount of LHRF in the serum of the intact donor rats.
- the third bar demonstrates a 450 per cent increase in the blood LH after administration of pure synthetic LHRF in an amount of l nanograms.
- the fourth bar demonstrates that the administration of serum from saline-treated hypophysectomized rats caused a 250 per cent increase in the concentration of LH in the blocked, ovariectomized rats.
- the final five bars summarize the data obtained upon administration of Pimozide and Fluspiriline in the stated amounts expressed in milligrams per kilogram body weight in conjunction with the same quantity of serum from hypophysectomized rats as was used in the fourth bar experiments.
- the data demonstrate a marked decrease in the quantity ofluteinizing hormone in the serum of the ovariectomized rats, indicating that administration of the two above named compounds reduces or eliminates the LHRF activity of the hypophysectomized animals.
- Pimozide was administered to an eight year old female patient (L.F.) presenting the classical clinical manifestation of the disease, for a period of eight months at a dose of 8.0 milligrams per day, orally, with a resulting demonstration of both objective and subjective improvement.
- Pimozide lowered the level of corticotropin-releasing factor and luteinizinghormone releasing factor in accordance with the data summarized in FIG. 2, which represents the results of the initial phase of the therapy trial.
- the CRF activity in the plasma of the patient was evaluated by the method of Arimura et. al., Endocrinology. 81,235 (1969) as modified by Upton and Amatruda, New England Journal of Med. 235 l96l p. 419.
- the LRF ac tivity was evaluated in the same manner as with the rat plasma discussed, supra.
- a process for reducing the activity of hypothalamic hypophysiotropic hormones in the blood plasma of an endocrinopathic patient which comprises chronically administering to a patient suffering therefrom. orally or parenterally, the compound 1-- ⁇ -1-[4,4-bis(p-fluorophenyl)butyl1-4-piperidyl1-2- benzimidazolinone, in an amount sufficient to alleviate the clinical characteristics of the endocrinopathy.
- a process for alleviating the clinical characteristics of the disease lipodystrophic diabetes which comprises chronically administering to a patient suffering from said disease, orally or parenterally, the compound 1-- ⁇ -l-[4,4-bis(p-fluorophenyl)butylj-4-piperidyll-2- benzimidazolinone in an amount sufficient to suppress the activity of the hypothalamic hypophysiotropic hormones in the blood plasma of said patient.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Endocrinopathic diseases induced by hypothalamic hyperfunction are amenable to treatment by Pimozide and Fluspiriline. Specifically, the clinical manifestations of lipodystrophic diabetes are alleviated by administration of either 1-(-(4,4-bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone or 8(4,4-bis(p-fluorophenyl)butyl)-1-phenyl-1,3,8-triazaspiro(4.5)decan-4-one to a patient suffering from the disease.
Description
United States Patent n 1 Corbin PROCESS FOR TREATING NEUROENDOCRINOPATHIC DISEASES EMPLOYING PlMOZlDE [75] Inventor: Alan Corbin, King of Prussia, Pa.
[73] Assignee: American Home Products Corporation, New York, NY.
[22] Filed: June 28, I973 [2l] Appl. No.: 374,454
[52] U.S. Cl. 424/267 [5]] Int. Cl A61k 27/00 [58] Field of Search 424/267 [56] References Cited OTHER PUBLICATIONS Jannssen et al., J. Clinical Pharm., Vol. I2 (I), pp.
[ Jan. 28, 1975 Primary Examiner-Vincent D. Turner Attorney, Agent, or Firm-Richard K. Jackson [57] ABSTRACT Endocrinopathic diseases induced by hypothalamic hypcrfunction are amenable to treatment by Pimozide and Fluspiriline. Specifically, the clinical manifestations of lipodystrophic diabetes are alleviated by administration of either l-{-[4,4-bis-(p-fluorophenyl) butyll-4-piperidyl}-2-benzimidaz0lin0ne or 8-[4,4- bis(p-flu0rophenyl)butyl I- I -pheny|-l ,3 ,8-triazaspiro- (4.5)decan-4-one to a patient suffering from the discase.
6 Claims, 2 Drawing Figures PROCESS FOR TREATING NEUROENDOCRINOPATHlCDISEASES EMPLOYING PlMOZlDE BACKGROUND OF THE lNVENTlON Various endocrinopathies, in which hypothalamic hyperfunction appears to be the prime cause of the endocrinopathology observed. are lipodystrophic diabetes, diabetes mellitus, acromegaly, ,Cushing's syndrome, Nelson's syndrone, Albright's syndrome. precocious puberty etc.
Exemplary of endocrinopathy is lipodystrophic diabetes, a rare and bizarre genetically transferred disease characterized by loss of subcutaneous and other body fat, skeletal and muscle over growth, splenomegaly and hepatomegaly due to fat infiltration, genital enlargement, hyperpigmentation with acanthosis nigricans, insulin-resistant hyperglycemia, hyperlipemia and hyperinsulinemia. Patients suffering from lipodystrophic diabetes, as opposed to normal subjects, exhibit detectable activities of releasing factors (corticotropin releasing factor CRF, follicle stimulating hormone releasing factor FRF, melanocyte stimulating hormone releasing factor MRF and luteinizing hormone releasing factor LRF) in their peripheral plasma. It has been established that CRF, FRF and LRF are present inperipheral plasma of ahypophysectomized human and that CRF, FRF and LRF are detectable in the peripheral plasma of hypophysectomized rats. l-leretofore, there has been no known effective treatment of patients suffering from lipodystrophic diabetes.
The compound {-1- 4,4-bis(p-fluorophenyl)butyl]4-piperidyl}2- benzimidazolinone is a known neuroleptic agent (J. Clinical Pharm., vol. 12 (1) pp. 26-34 (1972), commonly referred to as Pimozide, and presents the structure Likewise, the analogue 8-[4,4-bis(pfluorophenyl)butyl]-l-phenyl-l,3,6-triazaspiro (4.5)decan-4-one, is a known compound commonly referred to as Fluspiriline, which presents the structure DESCRIPTION OF THE INVENTION In accordance with this invention. there is provided a method for alleviating the clinical manifestations of endocrinopathies induced by hypothalamic hyperfunction which comprises administering an effective amount of either 1-- {-l-[4,4-bis(p-fluorophenyl)butyll-4-piperidyll-Z- benzimidazolinone or 8-l4.4-bis(p-fluorophenyl )butyll-phenyll ,3,8triazaspiro(4.5)decan-4-one to an afflicted patient.
More specifically there is provided a method for alleviating the clinical manifestations oflipodystrophic diabetes which comprises administering an effective amount of either 1-- {-l-[4,4-bis(p-fluorophenyl)butyl]-4-piperidyl}-2- benzimidazolinone or 8-[4,4-bis(pfluorophenyl)butyl l -phenyl-l ,3,8-triazaspiro( 4.5 decan-4-one to an afflicted patient.
By an effective amount, applicant intends to embrace that amount of the active ingredient which is necessary to cause regression of the observable physical and blood chemistry manifestations of the disease. ln practice, a dosage of 8.0 milligrams per day, administered orally, chronically, has been found to be effective in the treatment of lipodystrophic diabetes. Thus, depending upon the advancement stage of the disease and the gen eral physical condition and age of the patient, control of the disease is obtained by oral administration of 8.0 milligrams at intervals within the range of from 16 to 48 hours, chronically. Of course, the size of an individual dose as well as the regimen may be varied to achieve the desired results by the attending physician. In general, the dosage range for treatment of endocrinopathic diseases induced by hypothalamic hyperfunction is the same as that employed for the treatment of schizophrenia, or from about 4 to about 16 milligrams per day.
Both Pimozide and Fluspiriline may be administered orally or parenterally as neat or pure compounds without additives other than for purposes of providing suitable pharmaceutical solution or liquid suspension. However, conventional adjuvants known to the art may be combined with the active compounds of this invention to provide compositions and solutions if desired for producing tablets, capsules, injectables, and the like, without adverse effect upon the properties of the compounds.
The initial determination of the activity of Pimozide and Fluspiriline was conducted by the following test procedure, which is based upon the lack of any internal feed-back mechanism between the pituitary and hypothalamic functions in hypophysectomized rats. in essence, the presence of luteinizing hormonereleasing-factor in peripheral circulation of hypophysectomized rats, as opposed to intact rats, presents a dysfunction model in common with human patients suffering from lipodystrophic diabetes, for testing drugs which effect the hypothalamic releasing-factor mechanism. Thus, for example, a compound active in reducing the concentration of LH releasing-factor in peripheral circulation can be identified by observing the decrease of plasma LH increments in steroid-blocked ovariectomized rats treated with the plasma from the hypophysectomized rats.
The activity of Pimozide and Fluspiriline in reducing the concentration of luteinizing-hormone-releaserats which had been ovariectomized atleast 30 days prior to the study (200-250 grams initial body weight). Seventy-two hours prior to testing. the rats were blocked with.50 pg Estradiol Benzoate and 25 milligrams Progesterone in 0.25 milliliters corn oil. The change in luteinizing hormone in the recipient rats blood was determined in absolute level values by withdrawing an initial blood sample (1.0 ml.) from the anesthetized (ether) rat followed by a second blood sample (1.0 ml.) 20 minutes after administration of the peripheral plasma from the hypophysectomized female, Sprague-Dawley rat. The difference in luteinizing hormone content of the blood was determined from the preand post-treated assay rats and the data are expressed in terms of percentage change. The serum was assayed for luteinizing hormone according to the double antibody radioimmuno-assay procedure of G. N. Niswender et. al., Proc. Soc. Exp. Bio. Med., vol. 128, page 807 (1968). i
The accompanying FIG. 1 presents the results of the above described testing on a statistically significant number of standard experimental animals, the data for which is too voluminous to present in detail. In general the figure is self-explanatory, the vertical axis representing the percent change in luteinizing hormone found in the serum of the experimental animals. The first two bars of the graph represent the change observed upon administration of serum from normal (non-hypophysectomized) rats to the blocked, ovariectomized rats. The change in luteinizing hormone content of the recipient rats was quite small, demonstrating the absenceof any appreciable amount of LHRF in the serum of the intact donor rats. The third bar demonstrates a 450 per cent increase in the blood LH after administration of pure synthetic LHRF in an amount of l nanograms. The fourth bar demonstrates that the administration of serum from saline-treated hypophysectomized rats caused a 250 per cent increase in the concentration of LH in the blocked, ovariectomized rats. The final five bars summarize the data obtained upon administration of Pimozide and Fluspiriline in the stated amounts expressed in milligrams per kilogram body weight in conjunction with the same quantity of serum from hypophysectomized rats as was used in the fourth bar experiments. Thus, the data demonstrate a marked decrease in the quantity ofluteinizing hormone in the serum of the ovariectomized rats, indicating that administration of the two above named compounds reduces or eliminates the LHRF activity of the hypophysectomized animals.
To further demonstrate the effectiveness of the method of treating patients suffering from lipodystrophic diabetes, Pimozide was administered to an eight year old female patient (L.F.) presenting the classical clinical manifestation of the disease, for a period of eight months at a dose of 8.0 milligrams per day, orally, with a resulting demonstration of both objective and subjective improvement. Pimozide lowered the level of corticotropin-releasing factor and luteinizinghormone releasing factor in accordance with the data summarized in FIG. 2, which represents the results of the initial phase of the therapy trial. The CRF activity in the plasma of the patient was evaluated by the method of Arimura et. al., Endocrinology. 81,235 (1969) as modified by Upton and Amatruda, New England Journal of Med. 235 l96l p. 419. The LRF ac tivity was evaluated in the same manner as with the rat plasma discussed, supra.
The following table summarized the patients (L.F.) blood chemistry after about 9 months oftrcatment with Pimozide. demonstrating partial to complete normalization. ln the table. FSH means follicle stimulating hormone and LH means luteinizing hormone. SCOT means serum glutamic oxalic transaminase, and SGPT means serum glutamic pyruvate transaminase.
PLASMA CHEMISTRY OF PATIENT WITH LIPODYSTROPHIC DIABETES L.F.- Normal for L.F.-Prc Rx Pimozide Age & Scx
TOTAL LlPlDS g CHOLESTEROL g TRlGLYCERlDES (mg LlPEMlA (SERUM) TOTAL BlLlRUBlN (mg TRANSAMINASE 200 lll 2+ Clear Clear What is claimed is:
1. A process for reducing the activity of hypothalamic hypophysiotropic hormones in the blood plasma of an endocrinopathic patient which comprises chronically administering to a patient suffering therefrom. orally or parenterally, the compound 1-- {-1-[4,4-bis(p-fluorophenyl)butyl1-4-piperidyl1-2- benzimidazolinone, in an amount sufficient to alleviate the clinical characteristics of the endocrinopathy.
2. The process of claim 1 in which said compound is administered orally in an amount sufficient to at least partially normalize the activity of said hypophysiotropic hormones.
3. The process of claim 1 in which said compound is administered orally to said patient in an amount from about 4 to about 16 milligram per day, chronically.
4. A process for alleviating the clinical characteristics of the disease lipodystrophic diabetes which comprises chronically administering to a patient suffering from said disease, orally or parenterally, the compound 1-- {-l-[4,4-bis(p-fluorophenyl)butylj-4-piperidyll-2- benzimidazolinone in an amount sufficient to suppress the activity of the hypothalamic hypophysiotropic hormones in the blood plasma of said patient.
5. The process of claim 4 in which said compound is given orally at intervals from 16 hours to 48 hours in unit dosage form of from about 4 to about 16 milligrams.
6. The process of claim 5 in which said dosage unit is about 8.0 milligrams per day.
Claims (5)
- 2. The process of claim 1 in which said compound is administered orally in an amOunt sufficient to at least partially normalize the activity of said hypophysiotropic hormones.
- 3. The process of claim 1 in which said compound is administered orally to said patient in an amount from about 4 to about 16 milligram per day, chronically.
- 4. A process for alleviating the clinical characteristics of the disease lipodystrophic diabetes which comprises chronically administering to a patient suffering from said disease, orally or parenterally, the compound 1-(-1-(4,4-bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone in an amount sufficient to suppress the activity of the hypothalamic hypophysiotropic hormones in the blood plasma of said patient.
- 5. The process of claim 4 in which said compound is given orally at intervals from 16 hours to 48 hours in unit dosage form of from about 4 to about 16 milligrams.
- 6. The process of claim 5 in which said dosage unit is about 8.0 milligrams per day.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US374454A US3863011A (en) | 1973-06-28 | 1973-06-28 | Process for treating neuroendocrinopathic diseases employing pimozide |
| US480777A US3923993A (en) | 1973-06-28 | 1974-06-19 | Process for treating neuroendocrinopathic diseases employing fluspirilene |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US374454A US3863011A (en) | 1973-06-28 | 1973-06-28 | Process for treating neuroendocrinopathic diseases employing pimozide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3863011A true US3863011A (en) | 1975-01-28 |
Family
ID=23476896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US374454A Expired - Lifetime US3863011A (en) | 1973-06-28 | 1973-06-28 | Process for treating neuroendocrinopathic diseases employing pimozide |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US3863011A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2323385A1 (en) * | 1975-09-10 | 1977-04-08 | Janssen Pharmaceutica Nv | LACTATION STIMULATION COMPOSITION AND METHOD INCLUDING APPLICATION |
| WO1999059997A1 (en) * | 1998-05-18 | 1999-11-25 | Novo Nordisk A/S | Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes |
| US6277991B1 (en) | 1998-05-18 | 2001-08-21 | Novo Nordisk A/S | 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes |
-
1973
- 1973-06-28 US US374454A patent/US3863011A/en not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| Jannssen et al., J. Clinical Pharm., Vol. 12, (1), pp. 26-34 (1972) * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2323385A1 (en) * | 1975-09-10 | 1977-04-08 | Janssen Pharmaceutica Nv | LACTATION STIMULATION COMPOSITION AND METHOD INCLUDING APPLICATION |
| WO1999059997A1 (en) * | 1998-05-18 | 1999-11-25 | Novo Nordisk A/S | Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes |
| US6277991B1 (en) | 1998-05-18 | 2001-08-21 | Novo Nordisk A/S | 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bergen Jr et al. | Effect of an anion exchange resin on serum cholesterol in man. | |
| HAYS | Absorption of oral thyroxine in man | |
| BUCKMAN et al. | Estrogen potentiation of phenothiazine-induced prolactin secretion in man | |
| AMATRUDA JR et al. | A study of the mechanism of the steroid withdrawal syndrome. Evidence for integrity of the hypothalamicpituitary-adrenal system | |
| EP0204661A2 (en) | Sapogenin containing compositions for the treatment of obesity and diabetes | |
| WO2000053171A1 (en) | Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv | |
| Nagulesparen et al. | Bromocriptine treatment of males with pituitary tumours, hyperprolactinaemia, and hypogonadism | |
| US5891853A (en) | Compositions and methods for enhancement of dehydroepiandrosterone | |
| Crosignani et al. | Treatment of hyperprolactinemic states with different drugs: a study with bromocriptine, metergoline, and lisuride | |
| Wakabayashi et al. | Effect of pentobarbital and ether stress on serum prolactin levels in rats | |
| Frey et al. | Bioavailability of oral testosterone in males | |
| Burland et al. | Prolactin responses to cimetidine. | |
| Soffer et al. | The Presence of A» Gonadotrophin Inhibiting Substance «in Pineal Gland Extracts | |
| US3863011A (en) | Process for treating neuroendocrinopathic diseases employing pimozide | |
| MINTZ et al. | Effect of estrogen therapy on carbohydrate metabolism in acromegaly | |
| Belle et al. | Oral nicotinic acid for hyperlipemia∗: With emphasis on side effects | |
| US3923993A (en) | Process for treating neuroendocrinopathic diseases employing fluspirilene | |
| US7354906B2 (en) | Composition of anti-HIV drugs and anti-cortisol compounds and method for decreasing the side effects of anti-HIV drugs in a human | |
| Okihiro et al. | Hypokalemic periodic paralysis: experimental precipitation with sodium liothyronine | |
| Myren et al. | The early effect of trimipramine (Surmontil) on gastric secretion in man | |
| JPS6299323A (en) | Agent for hyperlipemia | |
| Friedman et al. | Effect of glucagon on blood-cholesterol levels in rats | |
| BR112020018362A2 (en) | COMPOSITION OF GLP-1 TO TREAT OBESITY AND WEIGHT CONTROL | |
| Kagan et al. | Vitamin A Metabolism in Infection Effect of Sterile Abscesses in the Rat on Serum and Tissue Vitamin A | |
| US3068148A (en) | Cis-cinnamic acid anti-inflammatory compositions and process of treating inflammation and capillary fragility |